About Wanbang Biopharma

HomeOur EnterpriseAbout Wanbang Biopharma

Overview

27

th

2022-2023 TOP 100 China Pharmaceutical Manufacturing Companies

National Level


High-tech Enterprises

7


7 Production Bases Across China

6000+


Total Employees of Wanbang Biopharma

27

th


2022-2023 TOP 100 China Pharmaceutical Manufacturing Companies

National Level


High-tech Enterprises

7


7 Production Bases Across China

6000+


Total Employees of Wanbang Biopharma

Wanbang Biopharmaceuticals Office Building

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member enterprise of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196-SH, 02196-HK). The company was established in 1981, earlier known as Xuzhou Biochemical Pharmaceutical Factory. In 1998, it was reorganized into Wanbang Biochemical Pharmaceutical; in 2001, it was changed to Wanbang Biopharmaceutical. In 2004, Wanbang joined with Fosun Pharma; and in 2017, it was upgraded to Wanbang Biopharmaceuticals (Group).

Wanbang Biopharma has established a domestic first-class R&D and manufacturing site for genetic engineering drugs for prokaryotic and eukaryotic cells. The research and development of recombinant human insulin and its analogues, recombinant human erythropoietin and other recombinant protein drugs take the leading position in China. The company invests about 10% of the sales revenues for new product research and development annually; it has a professional R&D team with over 400 personnel, more than 50% of whom are high-level personnel such as masters or PhDs, and apply for more than 50 national patents annually, and launch several new products into market.

Currently Wanbang Biopharma holds and controls 20 subsidiaries and has established more than 7 manufacturing sites across China. Wanbang Biopharma actively improve the quality system to international level. At present, more than 10 production lines have passed site inspection by overseas health authority and obtained certification, Among which, one sterile injectable production line has passed the EU and US FDA site inspection, and one oral solid preparation production line has passed the US FDA site inspection.

Products of Wanbang Biopharma market cover the fields of active chemical ingredients and their preparations, biochemical and biological products, traditional Chinese Medicine, etc. The company specializes in the research and development, production and sales of drugs in the treatment fields of hyperglycemia, hypertension, hyperlipidemia, hyperuricemia, and tumors. Animal source insulin, Youlitong® (Febuxostat Tablets), Yibao® (EPO), Wansuping® (Glimepiride Tablets), Keyuan® (Calcium Dobesilate Capsules), and heparin sodium has the market share among the best in China; Keyi® (Compound Aloe Capsules), Kesheng® (Xihuang Capsules), Xiaokekang Granules, and Dunye Tablets are exclusive products in China. So far, the company has more than 10 products with annual sales of over 100 million RMB.

Since the inception, Wanbang Biopharma has always adhered to good faith management, and has achieved excellent performance for 30 consecutive years of profitability and positive growth. The company has nationwide marketing network, and has established a number of self-operated marketing divisions such as prescription drugs, OTC and general products. The company also has complete marketing, business, and administrative support functions, meticulous patient education and customer service, steadily developed overseas business, rapidly grown internet business, and a marketing team with 3,000 personnel.

Wanbang always upholds the core value of “Self-improvement, Teamwork Spirit, Performance and Contribution to Society”, and actively create a corporate culture of "Army, School, Family" within the enterprise. The company vigorously introduces and cultivates talents, listens to employees' voices, pays attention to employees' demands, and provides employees with space and opportunities for learning, growth and development. It is committed to provide all staff, on the platform of Wanbang Biopharma, with a prosper career, a promising development, and prosperous income, as well as the joy of work and the warmth of home!

Wanbang Biopharma also actively takes social responsibilities, vigorously promote the construction of EHS system and continuously increase the public welfare donations (annually donate several million yuan on average). Project Bang, Wanbang Diabetes Family and Wanbang’s scholarship continue to enhance medical assistance, student grants, community care, etc., and have been highly valued from the whole society.

Expand All

Entrepreneurship

An entrepreneurial team is important core competitiveness for the development of Wanbang Biopharma. The executive team of Wanbang Biopharma has a unique strategic vision, able to assess the situation and proactively lay out the Wanbang's development, and actively creates "continuous innovation, pursue the ultimate "corporate culture atmosphere. They are full of passion, leading Wanbang to continue to innovate, endeavor to improve, and strive for excellence!

Executive Management

Shibin Wu

Secretary of the Party committee of Wanbang Biopharma 、Co Chairman、President and CEO
CPC member, Chemical & engineering majors, Senior engineer at the researcher level, EMBA in pharmacy of St. Joseph University, EMBA of CEIBS, Xuzhou representatives of the Party, members of the CPPCC, Xuzhou annual economic figure, Entrepreneurial mentor of China Torch Jiangsu, Xuzhou top talents, Xuzhou model worker, Vice President of China Biochemical Pharmaceutical Association, Executive director of Jiangsu Pharmaceutical Industry Association.
Shibin Wu

Secretary of the Party committee of Wanbang Biopharma 、Co Chairman、President and CEO

Shengli Li

Chairman and CEO of Wanbang Pharma Distribution
EMBA of Shanghai Jiaotong University.
Shengli Li

Chairman and CEO of Wanbang Pharma Distribution